Skip to main content
Clinical Trials/EUCTR2009-015780-14-AT
EUCTR2009-015780-14-AT
Active, not recruiting
Not Applicable

The effect of high dose remifentanil on the reversal of established sunburn-induced hyperalgesia in human volunteers - High-Dose-RemiSun

Abteilung für Anästhesie und Intensivmedizin, Medizinische Universität Wien0 sitesNovember 12, 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Volunteer study with 24 healthy volunteers to perform pain research and to study the reversal of hyperalgesia by IMP
Sponsor
Abteilung für Anästhesie und Intensivmedizin, Medizinische Universität Wien
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 12, 2009
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Abteilung für Anästhesie und Intensivmedizin, Medizinische Universität Wien

Eligibility Criteria

Inclusion Criteria

  • Men or women, aged between 19 and 40 years
  • Body mass index between 15th and 85th percentile
  • Normal findings in the medical history and physical examination
  • Drug free for 1 week prior to the study day
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Regular use of medication especially analgesics
  • Abuse of alcoholic beverages, drug abuse
  • History of asthma
  • Participation in a clinical trial in the 2 weeks preceding the study
  • Symptoms of a clinically relevant illness in the 2 weeks before the first study day
  • Resting systolic blood pressure \>135mmHg or diastolic blood pressure \>85mmHg
  • History of allergy to any of the medications used in the study
  • Pregnancy or breast feeding
  • Acute skin diseases like sunburn or skin lesions on the relevant areas and UV sensitive skin conditions, like Xeroderma pigmentosa

Outcomes

Primary Outcomes

Not specified

Similar Trials